Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Antibodies produced by a single clone of cells.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Antibodies reactive with HIV ANTIGENS.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Sites on an antigen that interact with specific antibodies.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Neoplasms containing cyst-like formations or producing mucin or serum.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Immunoglobulins produced in a response to FUNGAL ANTIGENS.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Tumors or cancer of the SKIN.
A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Antibodies elicited in a different species from which the antigen originated. These antibodies are directed against a wide variety of interspecies-specific antigens, the best known of which are Forssman, Hanganutziu-Deicher (H-D), and Paul-Bunnell (P-B). Incidence of antibodies to these antigens--i.e., the phenomenon of heterophile antibody response--is useful in the serodiagnosis, pathogenesis, and prognosis of infection and latent infectious states as well as in cancer classification.
Antibodies that can catalyze a wide variety of chemical reactions. They are characterized by high substrate specificity and share many mechanistic features with enzymes.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Tumors or cancers of the KIDNEY.
A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
Tumors or cancer of the LUNG.
Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
Tumors or cancer of the THYROID GLAND.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Established cell cultures that have the potential to propagate indefinitely.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Substances that are recognized by the immune system and induce an immune reaction.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the LIVER.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
DNA present in neoplastic tissue.
Substances elaborated by bacteria that have antigenic activity.
Proteins prepared by recombinant DNA technology.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A general term for various neoplastic diseases of the lymphoid tissue.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Tumors or cancer of the PAROTID GLAND.
A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.
The sum of the weight of all the atoms in a molecule.
Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Substances elaborated by viruses that have antigenic activity.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Elements of limited time intervals, contributing to particular results or situations.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Tumors or cancer of the ENDOCRINE GLANDS.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Tumors or cancer of the COLON.
Tumors or cancer of the EYE.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Techniques used to demonstrate or measure an immune response, and to identify or measure antigens using antibodies.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.
Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.
Tumors or cancer of the NOSE.
EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.
Tumors or cancer of the SALIVARY GLANDS.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains.
A benign epithelial tumor with a glandular organization.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumors or cancer of the UTERUS.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
Techniques for removal by adsorption and subsequent elution of a specific antibody or antigen using an immunosorbent containing the homologous antigen or antibody.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
Antibodies obtained from a single clone of cells grown in mice or rats.
The phenomenon of immense variability characteristic of ANTIBODIES. It enables the IMMUNE SYSTEM to react specifically against the essentially unlimited kinds of ANTIGENS it encounters. Antibody diversity is accounted for by three main theories: (1) the Germ Line Theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; (2) the Somatic Mutation Theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and (3) the Gene Rearrangement Theory, which holds that antibody diversity is generated by the rearrangement of IMMUNOGLOBULIN VARIABLE REGION gene segments during the differentiation of the ANTIBODY-PRODUCING CELLS.
Tumors or cancer located in bone tissue or specific BONES.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the INTESTINES.
A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.
An encapsulated lymphatic organ through which venous blood filters.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
A malignant epithelial tumor with a glandular organization.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Tumors or cancer of the human BREAST.
Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Tumors or cancer of the BILE DUCTS.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
Tumors or cancer of the SPLEEN.
Neoplasms composed of more than one type of neoplastic tissue.
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
Resistance to a disease-causing agent induced by the introduction of maternal immunity into the fetus by transplacental transfer or into the neonate through colostrum and milk.
Tumors or cancer of the MANDIBLE.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Antibodies specific to INSULIN.
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
Field of chemistry that pertains to immunological phenomena and the study of chemical reactions related to antigen stimulation of tissues. It includes physicochemical interactions between antigens and antibodies.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Tumors or cancer of the STOMACH.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
Cancer or tumors of the MAXILLA or upper jaw.
Diagnostic procedures involving immunoglobulin reactions.
Glycoproteins found on the membrane or surface of cells.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Tumors or cancer of the anal gland.
The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
The rate dynamics in chemical or physical systems.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN.
Polysaccharides found in bacteria and in capsules thereof.
A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.

Immune responses to all ErbB family receptors detectable in serum of cancer patients. (1/1721)

Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4. Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4. Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3. Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates. Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in light of immunotherapeutic approaches targeting these receptors.  (+info)

Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. (2/1721)

p53 alterations are considered to be predictive of poor prognosis in hepatocellular carcinoma (HCC) and may induce a humoral response. Anti-p53 serum antibodies were assessed by enzyme-linked immunosorbent assay (ELISA) using purified recombinant human p53 on 130 European HCC patients before treatment and during the clinical course of the disease. p53 immunohistochemistry was performed on tumours from the 52 patients who underwent surgery, and DNA sequencing analysis was initiated when circulating anti-p53 antibodies were detected. Nine (7%) HCC patients had anti-p53 serum antibodies before treatment. During a mean period of 30 months of follow-up, all the negative patients remained negative, even when recurrence was observed. Of the nine positive patients, eight were still positive 12-30 months after surgery. The presence of anti-p53 serum antibodies was correlated neither with mutation of the p53 gene nor the serum alpha-fetoprotein levels and clinicopathological characteristics of the tumours. However, a greater incidence of vascular invasion and accumulation of p53 protein were observed in the tumours of these patients (P<0.03 and P<0.01 respectively) as well as a better survival rate without recurrence (P = 0.05). In conclusion, as was recently shown in pancreatic cancer, anti-p53 serum antibodies may constitute a marker of relative 'good prognosis' in a subgroup of patients exhibiting one or several markers traditionally thought to be of bad prognosis.  (+info)

Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library. (3/1721)

To identify the epitope of the melanoma-associated chondroitin sulfate proteoglycan (MCSP) recognized by the monoclonal antibody (mAb) 763.74, we first expressed random DNA fragments obtained from the complete coding sequence of the MCSP core glycoproteins in phages and selected without success for binders to the murine mAb 763.74. We then used a library of random heptapeptides displayed at the surface of the filamentous M13 phage as fusion protein to the NH2-terminal portion of the minor coat protein III. After three rounds of selection on the bound mAb, several phages displaying related binding peptides were identified, yielding the consensus sequence Val-His-Leu-Asn-Tyr-Glu-His. Competitive ELISA experiments showed that this peptide can be specifically prevented from binding to mAb 763.74 by an anti-idiotypic MK2-23 mouse:human chimeric mAb and by A375 melanoma cells expressing the antigen MCSP. We screened the amino acid sequence of the MCSP molecule for a region of homology to the consensus sequence and found that the amino acid sequence Val-His-Ile-Asn-Ala-His spanning positions 289 and 294 has high homology. Synthetic linear peptides corresponding to the consensus sequence as well as to the MCSP-derived epitope inhibit the binding of mAb 763.74 to the phages displaying the consensus amino acid sequence. Finally, the biotinylated consensus peptide absorbed to streptavidin-microtiter plates can be used for the detection of mAb 763.74 in human serum. These results show clearly that the MCSP epitope defined by mAb 763.74 has been identified.  (+info)

A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa. (4/1721)

In this study we performed N-terminal sequence analysis of gp20, a 20 kDa sialoglycoprotein on the human sperm surface previously identified by radiolabelling of the sialic acid residues of sperm surface. We found 100% identity with the N-terminus of CD52, an antigen expressed on almost all human leukocytes. We also show that, like CD52, gp20 behaves as a glycosylphosphatidylinositol (GPI)-anchored protein and that anti-gp20 antiserum reacts with an antigen on leukocytes of the same molecular weight as CD52. Using CAMPATH-1, the monoclonal antibody against CD52, in fluorescent staining of capacitated spermatozoa, Western blot analysis and the zona-free hamster egg penetration test, we found that the effect of this antibody was different from that of our anti-gp20. Western blot analysis revealed a well-defined 20 kDa band with anti-gp20, whereas a 14-20 kDa band was detected with CAMPATH-1. Anti-gp20 stained the equatorial region of the sperm head, whereas CAMPATH-1 stained the tail in immunofluorescence analysis of capacitated spermatozoa. A dose-dependent inhibitory effect was seen with CAMPATH-1, similar to that previously detected with anti-gp20, in a zona-free hamster egg penetration test. However, with CAMPATH-1 agglutination of motile spermatozoa was detected, and this was not present with anti-gp20. This suggests that the epitopes recognized by the two antibodies are different.  (+info)

Adoptive immunotherapy of a Gross virus producing lymphoma and a methylcholanthrene-induced fibrosarcoma in tolerant rats. (5/1721)

Immunological tolerance to Gross virus-specific transplantation antigens in rats given neonatae transfer of donor lymphoid cells beneath the kidney capsule of syngeneic recipient rats. Immune or normal donor cells invariably developed a cell-mediated immune reaction in kidneys of GV-tolerant recipients, presumably against GV antigens present on the surface of recipient lymphoid cells in the kidney. Spleen and lymph node cells from tolerant rats failed to develop a reaction in tolerant recipients, but developed a strong reaction to histoincompatible antigens in the kidneys of semisyngeneic tolerant rats. The immunologically tolerant state in the rats could be broken by adoptive transfer of spleen and lymph node cells from syngeneic rats immunized with GV-induced lymphoma cells. Immunotherapy of a GV-induced and also a GV-infected methylcholanthrene-induced fibrosarcoma growing in tolerant rats was successful when immune spleen and lymph node cells were administered i.p. 3 days after s.c. inoculation of 2 X 10(7) tumor cells in the case of the lymphoma, and 1 day after inoculation of 5 X 10(6) tumor cells in the case of the fibrosarcoma.  (+info)

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. (6/1721)

PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is directed against the Lewis-Y antigen, which is expressed on 75% of all breast cancers but is limited in expression on normal tissues. Preclinical xenograft models demonstrated significant antitumor activity, including cures. A randomized phase II design was chosen to estimate the activity of the BR96-doxorubicin conjugate in metastatic breast cancer in a study population with confirmed sensitivity to single-agent doxorubicin. PATIENTS AND METHODS: Patients with measurable metastatic breast cancer and immunohistochemical evidence of Lewis-Y expression on their tumor received either BR96-doxorubicin conjugate 700 mg/m2 IV over 24 hours or doxorubicin 60 mg/m2 every 3 weeks. Patients were stratified on the basis of prior doxorubicin exposure, visceral disease, and institution. Cross-over to the opposite treatment arm was allowed with progressive or persistently stable disease. RESULTS: Twenty-three patients who had received a median of one prior chemotherapy regimen were assessable. There was one partial response (7%) in 14 patients receiving the BR96-doxorubicin conjugate and one complete response and three partial responses (44%) in nine assessable patients receiving doxorubicin. No patient experienced a clinically significant hypersensitivity reaction. The toxicities were significantly different between the two treatment groups, with the BR96-doxorubicin conjugate group having limited hematologic toxicity, whereas gastrointestinal toxicities, including marked serum amylase and lipase elevations, nausea, and vomiting with gastritis, were prominent. CONCLUSION: The BR96-doxorubicin immunoconjugate has limited clinical antitumor activity in metastatic breast cancer. The gastrointestinal toxicities likely represent binding of the agent to normal tissues expressing the target antigen and may have compromised the delivery of the immunoconjugate to the tumor sites.  (+info)

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. (7/1721)

PURPOSE: In patients undergoing cytokine therapy, systemically applied interleukin-2 (IL-2) and/or interferon-alpha (IFN-alpha) have been reported to induce thyroid dysfunction as well as thyroid autoantibodies. We analyzed the correlation of thyroid autoimmunity with HLA phenotype, various other autoimmune parameters, and patient survival. PATIENTS AND METHODS: For this purpose, antithyroglobulin autoantibodies, antimicrosomal thyroid autoantibodies, thyroglobulin receptor autoantibodies, thyroid dysfunction, and multiple clinical parameters were determined in 329 unselected patients with metastatic renal cell cancer before and after systemic IL-2 and IFN-alpha2 therapy. For statistical analysis, we used both univariate and multivariate Cox proportional hazards models and the two-tailed Fisher's exact test. RESULTS: Antithyroglobulin autoantibodies and antimicrosomal thyroid autoantibodies were detected in 60 patients (18%); positive autoantibody titers of various other autoimmune parameters were statistically unrelated. The presence of thyroid autoantibodies was correlated with prolonged survival (P<.0001). There was a statistically significant difference in frequencies of HLA-Cw7 expression between thyroid autoantibody-positive and -negative patients (P< or =.05), and the Cw7 expression was associated with prolonged overall survival (P = .009). CONCLUSION: The evaluation of thyroid autoantibodies during cytokine therapy could be a useful prognostic marker for patients with renal cell carcinoma who benefit from cytokine treatment. IL-2- and IFN-alpha2-induced tumor control and prolonged survival may require breaking of immunologic tolerance against self-antigens.  (+info)

Prognostic value of p53 genetic changes in colorectal cancer. (8/1721)

PURPOSE: To explore whether there is a linkage between different mutations in the p53 gene in primary colorectal cancer and the risk of death from colorectal cancer in a large group of patients with long follow-up. We also compared a complementary DNA-based sequencing method and an immunohistochemical (IHC) method for detecting p53 protein overexpression in colorectal cancer. MATERIALS AND METHODS: The entire coding region of the p53 gene was sequenced in 191 frozen tumor samples collected from January 1988 to November 1992. RNA was extracted and synthesized to cDNA. p53 was amplified by the polymerase chain reaction, and the DO-7 monoclonal antibody was used in the IHC assessments. RESULTS: Mutations were detected in 99 samples (52%) from 189 patients. There was a significant relationship between the p53 mutational status and the cancer-specific survival time, with shorter survival time for patients who had p53 mutations than for those who did not (P = .01, log-rank test). Mutations outside the evolutionarily conserved regions were associated with the worst prognosis. Multivariate analysis showed that the presence of p53 mutations was an independent prognostic factor (relative hazard, 1.7, P = .03). There was no significant relationship between overexpression of p53 protein, as determined by IHC analysis, and cancer-specific survival. CONCLUSION: Mutational analyses of the p53 gene, using cDNA sequencing in colorectal cancer, provide useful prognostic information. In addition, cDNA sequencing gives better prognostic information than IHC assessment of p53 protein overexpression.  (+info)

This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced
Open label multicenter, two-step, non-randomized (pilot) study to analyze the safety of 4 cycles of 3-day 40mg/m2 oral fludarabine with simultaneous thrice weekly application of 30mg alemtuzumab s.c. in patients with B-CLL disease in 1st and 2nd relapse after any primary treatment or with disease refractory to any therapy in 1st or 2nd line (including Fludarabine, ). This regimen is preceded by an escalation phase with 3-10-30 mg of alemtuzumab s.c.. After the first phase (completed treatment of 7 patients) an interim analysis of safety and efficacy will be performed. In case of a sufficient risk benefit assessment followed by the enrollment of further 21 patients. Final analysis of safety and preliminary efficacy will be based on all patients enrolled. ...
The screening of cDNA expression libraries derived from human tumors with autologous antibody (SEREX) is a powerful method for defining the structure of tumor antigens recognized by the humoral immune system. Sixty-five distinct antigens (NY-REN-1 to NY-REN-65) reactive with autologous IgG were iden …
Every participant had received active treatment; there was no placebo. Participants who qualified were randomly assigned to treatment with either alemtuzumab or SC interferon beta-1a at a 2:1 ratio (that is, 2 given alemtuzumab for every 1 given interferon beta-1a). Alemtuzumab was administered in two annual courses, once at the beginning of the study and again 1 year later. Interferon beta-1a was self-injected 3 times per week for 2 years. All participants were required to return to their study site every 3 months for neurologic assessment. In addition, safety-related laboratory tests were performed at least monthly. Participation in this study ended 2 years after the start of treatment for each participant. Additionally, participants who received alemtuzumab might be followed in CAMMS03409 (NCT00930553) an extension study for safety and efficacy assessments. Participants who received interferon beta-1a and completed 2 years on study might be eligible to receive alemtuzumab on the extension ...
Alemtuzumab is used in the treatment of blood cancer (chronic lymphocytic leukemia),multiple sclerosis (ms).get complete information about alemtuzumab including usage, side effects, drug interaction, expert advice along with medicines associated with alemtuzumab at
In an analysis of in periods of yore unpublished position III data, U.K. researchers broadcast a oversized, speedy repopulation of a subset of B waste times without vigorous T-cell contribution in patients with multiple sclerosis (MS) enquired with alemtuzumab (Lemtrada), which rule have authored an environment for ancillary autoimmune sickness.. Pumping lymphocyte reconstitution subject-matter from the cardinal Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I and II (CARE-MS I and II) readings, Klaus Schmierer, PhD, FRCP, of Ruler Mary University of London, and joins found that alemtuzumab depleted CD4 T foot-draggings by more than 95%, off regulatory areas and CD8 T cells, which corpsed affectionately deeper testimonial levels globally in the trials. Although the fussy also initially depleted CD19 B corrals by more than 85%, new B apartments distended by 180% and transmuted to season B chambers as a remainder straightaway. These interchanges were associated with the armada ...
CAMPATH (Alemtuzumab) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
Id like to share with you that I received alemtuzumab (Campath trade name) in the hospital 26.04. - 30/04/2011 under the program CARE MS II extension study. Side effects of alemtuzumab infusions continue after I get tired, the most troublesome ...
Mouse monoclonal CD13 antibody [CC81] validated for Flow Cyt and tested in Cow. Immunogen corresponding to tissue, cells or virus
Mouse monoclonal WC1 antibody [CC101] validated for IP, IHC, Flow Cyt and tested in Cow and Pig. Immunogen corresponding to tissue, cells or virus
CD1w3 antibody [CC43] for FACS, IP. Anti-CD1w3 mAb (GTX42307) is tested in Goat, Sheep, Bovine, Sheep samples. 100% Ab-Assurance.
Wc1 antibody [CC15] (FITC) (CD163 molecule-like 1) for FACS. Anti-Wc1 mAb (GTX43329) is tested in Goat, Sheep, Bovine, Sheep samples. 100% Ab-Assurance.
1AD9: VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs.
I was in the CAMMS323 trial and I received Campath (although I still do not know the dosage). I was only diagnosed with RRMS for one year and 2 months before going into the trial. I am currently at month ...
Learn ways to provide support to your loved ones with relapsing MS, hear advice from other Care Partners, and see what Care Partners mean to MS patients.
引用Abcams Anti-p38抗体[M138] (ab31828)的参考文献列表。为您列举引用本产品的发表文章,并提供信息包括论文文献数据库中的检索编号以便您搜寻文章
BACKGROUND: Calcineurin inhibitors (CNIs) reduce short-term kidney transplant failure, but might contribute to transplant failure in the long-term. The role of alemtuzumab (a potent lymphocyte-depleting antibody) as an induction treatment followed by an early reduction in CNI and mycophenolate exposure and steroid avoidance, after kidney transplantation is uncertain. We aimed to assess the efficacy and safety of alemtuzumab-based induction treatment compared with basiliximab-based induction treatment in patients receiving kidney transplants. METHODS: For this randomised trial, we enrolled patients aged 18 years and older who were scheduled to receive a kidney transplant in the next 24 h from 18 transplant centres in the UK. Using minimised randomisation, we randomly assigned patients (1:1; minimised for age, sex, and immunological risk) to either alemtuzumab-based induction treatment (ie, alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids) or basiliximab-based induction
A 64-year-old woman, with unremarkable previous medical history, was diagnosed with T cell prolymphocytic leukemia in 2006. She received alemtuzumab (30 mg subcutaneously thrice weekly) as first line chemotherapy; combined therapy of valaciclovir and trimethoprim-sulfamethoxazole, for anti-infective prophylaxis, was initiated simultaneously. Before institution of alemtuzumab therapy, full blood cell count disclosed the following: hemoglobin 12.7 g/dL, white blood cell count 88×109/L (absolute neutrophil count: 8.5×109/L, lymphocyte: 79.5×109/L, platelets: 400,000/mm3). Two days after the 9th alemtuzumab injection, the patient exhibited an asymptomatic reactivation of cytomegalovirus (CMV) infection; she was given valganciclovir therapy for 21 days.. Three days after the 16th alemtuzumab injection, she was admitted with a 2-day history of abdominal pain. On admission, the patient was febrile (38°5C); physical examination showed a tenderness in the appendicular area. Laboratory findings ...
The randomized Haemato Oncology Foundation for Adults in The Netherlands 68 phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 monoclonal antibody alemtuzumab for high-risk chronic lymphocytic leukemia, defined as at least 1 of the following: unmutated immunoglobulin heavy chain genes, deletion 17p or 11q, or trisomy 12. Fit patients were randomized to receive either 6 28-day cycles of oral FC chemotherapy (days 1 through 3: fludarabine 40 mg/m(2) per day and cyclophosphamide 250 mg/m(2) per day: n = 139) or FC plus subcutaneous alemtuzumab 30 mg day 1 (FCA, n = 133). FCA prolonged the primary end point, progression-free survival (3-year progression-free survival 53 vs 37%, P = .01), but not the secondary end point, overall survival (OS). However, a post hoc analysis showed that FCA increased OS in patients younger than 65 years (3-year OS 85% vs 76%, P = .035). FCA also increased the overall response rate (88 vs 78%, P = .036), and the bone marrow minimal residual ...
Recent clinical outcomes and subsequent approvals of anti-CTLA-4 and anti-PD-1 checkpoint blockade antibodies, which mitigate inhibitory signaling that decreases antitumor T cell responses, have ignited extraordinarily broad efforts to develop the potential of cancer immunotherapy (Pardoll, 2012; Topalian et al., 2015). Unlike strategies that typically elicit antitumor responses of limited duration and nearly inevitable treatment resistance, immunotherapeutics can achieve durable and long-lasting antitumor responses in a minority of patients with advanced disease (Sharma and Allison, 2015). To build upon this success, combination immunotherapies are a next logical step (Gajewski et al., 2013; Spranger and Gajewski, 2013).. One such approach combines a tumor-specific antibody to drive antibody-dependent cell-mediated cytotoxicity (ADCC) through neutrophil- and eosinophil-mediated attack and an extended serum half-life IL-2 fusion to activate CD8+ T cells and NK cells. However, this strategy is ...
A radioimmunoconjugate of the humanized monoclonal antibody CC49 labeled with iodine I 131. Iodine I 131 monoclonal antibody CC49 delivers beta and gamma radiation-emitting I 131 radionuclide specifically to tumor cells that express tumor-associated glycoprotein (TAG)-72, allowing localization of TAG-72-expressing tumor cells with radioimaging devices in diagnostic applications or resulting in specific TAG-72-expressing tumor cell radiocytotoxicity in therapeutic applications. Monoclonal antibody CC49 binds to TAG-72, a pancarcinoma antigen, with high affinity.. ...
Alemtuzumab, an anti-CD52 monoclonal antibody, was administered to patients with RA between 1991 and 1994. We have followed a cohort of recipients since that time and previously reported significant delays in immune reconstitution. Here we report |20 years of follow-up data from this unique cohort. Surviving alemtuzumab recipients were age, sex and disease duration matched with RA controls. Updated mortality and morbidity data were collected for alemtuzumab recipients. For both groups antigenic responses were assessed following influenza, Pneumovax II and combined diphtheria/tetanus/poliovirus vaccines. Circulating cytokines and lymphocyte subsets were also quantified. Of 16 surviving alemtuzumab recipients, 13 were recruited: 9 recipients underwent a full clinical assessment and 4 had case notes review only. Since our last review 10 patients had died from causes of death consistent with long-standing RA, and no suggestion of compromised immune function. Compared with controls the alemtuzumab cohort had
Nishioka, K; Irie, R F.; Kawana, T; and Takeuchi, S, Immunological studies on mouse mammary tumors. Iii. Surface antigens reacting with tumor-specific antibodies in immune adherence. (1969). Subject Strain Bibliography 1969. 1210 ...
In a prospective phase III study in Germany,[155] patients were randomly allocated either no treatment or alemtuzumab 30 mg intravenously three times a week for 12 weeks, beginning a median of 67 days after the last dose of induction chemotherapy (fludarabine with or without cyclophosphamide). Although recruitment to this trial was halted at 21 patients because of severe infections in the alemtuzumab group, those allocated alemtuzumab had significantly longer progression-free survival than those assigned no treatment. Using a very sensitive PCR-based assay with sequence-specific primers to detect minimal residual disease, five of six patients tested became negative for minimal residual disease. Findings of a phase II study156 of alemtuzumab given in doses of 10 mg subcutaneously three times a week for 6 weeks, beginning not less than 8 weeks after discontinuation of fludarabine induction chemotherapy, proved that this regimen was safe and able to turn partial remissions into complete remissions. ...
Alemtuzumab (marketed as Campath or Campath-1H) is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia (CLL) and T-cell lymphoma. Alemtuzumab targets CD52, a protein present on
1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnol 2005; 23: 1147-1157. 2. Klener P, Klener P jr. Nová protinádorová léčiva a léčebné strategie v onkologii Grada Publishing a.s. Praha, 2010. 3. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Natur Rev 2010; 10: 317-327. 4. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkinęs lymphoma. Drugs 2007; 67: 333-350. 5. Belada D. Monoklonální protilátky v léčbě lymfomů. Remedia 2008; 6: 416.423 6. Castillo J, Winer E, Quinsberry O. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36: 755-768. 7. Wierda WG, Kipps TJ, Keatimg MJ, et al. Self-administered. subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2011; 117: 116-124. 8. Khubchandani S, Czuczman MS, Hernandes-Ilizalituri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of ...
INTRODUCTION: Alemtuzumab is a humanised anti-CD52 mAb which has recently been licensed for the treatment of relapsing multiple sclerosis in Europe. AREAS COVERED: The efficacy and safety of alemtuzumab from open label, Phase II and Phase III trials is reported. EXPERT OPINION: Alemtuzumab causes rapid and profound complement mediated lysis of circulating lymphocytes and allows beneficial modulation of the immune system during a subsequent reconstitution phase. Clinical trials have demonstrated superior efficacy against an active comparator, with reduction in annualised relapse rates and sustained accumulation of disability at 3 years and sustained efficacy at 5 years. The main adverse effects are mild to moderate infusion reactions, an increased incidence of mild to moderate infections and autoimmune adverse events. Thyroid disorders are the most common form of autoimmune adverse events, occurring in approximately one third of patients. Overt Graves hyperthyroidism represents approximately ...
The right thing to do is to is to figure out how to prevent MS in future generations. Forget the DMTs and trials into progressive MS; lets just start from a clean slate. Its unfortunate that we have MS but lets bite the bullet and shift our focus on newborns. Lets make them vitamin D replete. Let us be the last generation to have lived and died with MS. Weve had our moment. Lets accept our fate and live with it rather than drugging ourselves with crap our bodies cant handle. The only reason a MSer will run the risk of taking alemtuzumab is because of desperation. Desperate people are always living in danger. MS can be prevented but its dangerous to think that modern toxins will, somehow, cure it ...
Patient Guide Important information for patients starting therapy with LEMTRADA (alemtuzumab) This medicinal product is subject to additional monitoring. This will allow quick identification of new safety
This is a study designed to test whether giving alemtuzumab on a maintenance schedule will prolong the time until the patient requires chemotherapy.
View: Main AbID Search Nested - start */ /* ----------------------------------------- */ .entry-content thead th a {padding:0!important;}tr{ -webkit-transition: all .35s ease-in-out; /* Safari 3.1 to 6.0 */ transition: all .35s ease-in-out; } /* ----------------------------------------- */ /* View: Main AbID Search Nested - end */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* View: List of Antibodies from Antibody ID Ecomm - start */ /* ----------------------------------------- */ .entry-content thead th a {padding:0!important;} /* ----------------------------------------- */ /* View: List of Antibodies from Antibody ID Ecomm - end */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* View: ProductsInAntibodyTbl - start */ /* ----------------------------------------- */ a.productappearance{ display:inline-block; font-size:80%; padding:3px; background:gray; color:white!important; ...
Unfortunately, there is no cure for multiple sclerosis, however, there are several different options for treating the condition. Find out about specialists who treat the disease and forms of treatment... ...
Alemtuzumab is a highly effective drug for multiple sclerosis, approved in more than 60 countries and used by more than 12,000 patients worldwide.
Lemtrada (alemtuzumab) - IV infusion given over the course of 5 consecutive days, followed 1 year later with a 3 day consecutive course
Lemtrada (alemtuzumab) - IV infusion given over the course of 5 consecutive days, followed 1 year later with a 3 day consecutive course
Allogeneic hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning (RIC) offers a potential cure for patients with myelodysplastic syndrome (MDS) who are ineligible for standard-intensity regimens. Previously published data from our institution suggest excellent outcomes at 1 yr using a uniform fludarabine, busulfan, and alemtuzumab-based regimen. Here we report long-term follow-up of 192 patients with MDS and acute myelogenous leukemia (AML) secondary to MDS (MDS-AML) transplanted with this protocol, using sibling (n = 45) or matched unrelated (n = 147) donors. The median age of the cohort was 57 yr (range, 21 to 72 yr), and median follow-up was 4.5 yr (range, 0.1 to 10.6 yr). The 5-yr overall survival (OS), event-free survival, and nonrelapse mortality were 44%, 33%, and 26% respectively. The incidence of de novo chronic graft-versus-host disease (GVHD) was low at 19%, illustrating the efficacy of alemtuzumab for GVHD prophylaxis. Conversely, the 5-yr relapse rate ...
Link to Pubmed [PMID] - 9309422. Hybridoma 1997 Aug;16(4):317-24. We report here the first amino acid sequence of an anti-Tn monoclonal antibody raised against human breast cancer cells and show that a single chain Fv fragment of this IgM retains the Tn-binding specificity as defined by functional assays with asialo-OSM and membrane extracts from MCF-7 cells. Sequence comparisons and molecular modeling of 83D4 indicate that the antibody combining site displays a cavity-like feature primarily defined by the CDR H1 and H2 loops. This pocket could accommodate a single Tn molecule, thus, suggesting a structural explanation for the predominant expression of a particular VH gene segment in a group of antibodies that recognize tumor-associated antigens arising from an aberrant O-glycosylation.. ...
CAMPATH-1 (CDw52) antibodies recognize a very small lipid-anchored glycoprotein that is expressed on the surface of human lymphocytes. They are remarkably lytic with human complement. In addition, CAMPATH-1G (rat IgG2b) and CAMPATH-1H (human IgG1) bind to human Fc receptors and are very effective for cell lysis in vivo. CAMPATH-1M (rat IgM) and CAMPATH-1G have been used to control GVHD and graft rejection in bone marrow transplantation by depletion of the T cells of the donor and recipient. Depletion of donor T cells alone gave excellent control of GVHD but up to 20% of the patients transplanted from HLA-matched siblings, and 51% of those transplanted from nonsibling donors, experienced graft failure caused by immunological rejection. Graft rejection could be partly overcome by additional immunosuppression either with CsA or total lymphoid irradiation (TLI). More effective was the use of CAMPATH-1G in vivo to deplete residual host lymphocytes. Preliminary results from current protocols of antibody
Abstract. Background: Acute graft-versus-host disease (GvHD) is mediated by activated T lymphocytes. Alemtuzumab is an unconjugated, humanized IgG1 kappa monoc
Colorful World of Quantum Dots. A few imaging applications using quantum dots (QDs) will be introduced, which will cover from visible to infrared(IR) for the wavelengths and from cellular super-resolution to whole body in vivo imaging for the object scale. (1) QDs were conjugated to tumor-specific antibodies(Abs) with zwitterionic surface coating to reduce nonspecific bindings. The Ab-QD probes were used to diagnose tumors for sectioned mouse tissues, fresh mouse colons stained ex vivo and in vivo, and also for fresh human colon adenoma tissues. The probes successfully detected not only cancers that are readily discernible by bare eyes but also hyperplasia and adenoma regions. Multiplexed QD, spray-and-wash, and endoscopy approach provided a significant advantage for detecting small or flat tumors that may be missed by conventional endoscopic examinations. QD-Ab probe was also used in conjunction with a ratiometric fluorescent molecular probe, cresyl violet-glutamic acid derivative, that ...
Alemtuzumab is a humanized monoclonal antibody against CD52 (cluster of differentiation 52) and is approved for the therapy of relapsing-remitting multiple sclerosis. The application of alemtuzumab leads to a rapid, but long-lasting depletion predominantly of CD52-bearing B and T cells with reprogramming effects on immune cell composition resulting in the restoration of tolerogenic networks. Alemtuzumab has proven high efficacy in clinical phase II and III trials, where interferon β-1a was used as active comparator. However, alemtuzumab is associated with frequent and considerable risks. Most importantly secondary autoimmune disease affects 30%-40% of patients, predominantly impairing thyroid function. Extensive monitoring and early intervention allow for an appropriate risk management. However, new and reliable biomarkers for individual risk stratification and treatment response to improve patient selection and therapy guidance are a significant unmet need. Only a deeper understanding of the
Mechanism of Action Alemtuzumab (Campath-1H) is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (,95%) normal lymphocytes, and T-cell & B-cell lymphoma cells. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and antitumour T-cell activity. Alemtuzumab has been used for chronic lymphocytic leukemia, low grade lymphomas and other non-cancerous indications.. ...
|strong|Human Anti-CD52 Antibody|/strong|, clone Campath-1H is a research grade biosimilar of the monoclonal antibody drug alemtuzumab. It is a recombinant human IgG1 kappa antibody with variable regi…
OBJECTIVE: To examine alemtuzumab efficacy in treatment-naive patients with highly active relapsing-remitting MS (RRMS). BACKGROUND: In CARE-MS I (NCT00530348), alemtuzumab significantly reduced clinical and MRI disease activity versus SC IFNB-1a over 2 years in the highly active patient subgroup. Efficacy was durable through 4 years, despite most receiving no therapy since Month 12. DESIGN/METHODS: Patients received courses of alemtuzumab at baseline and Month 12 in the core study. Patients could enter the extension (NCT00930553), with as-needed retreatment for relapse or radiological activity, or another disease-modifying therapy (DMT) at the investigators discretion. Highly active disease was ≥2 relapses in year before randomization and ≥1 baseline gadolinium-enhancing lesion. No evidence of disease activity (NEDA) was absence of MRI (new gadolinium-enhancing and new/enlarging T2 lesions) and clinical (6-month confirmed disability progression or relapse) activity. Brain volume loss was ...
View more ,Background: In the 2-year (y) CARE-MS II phase 3 trial (NCT00548405), alemtuzumab (12 mg/day; baseline: 5 consecutive days; 12 months later: 3 consecutive days) significantly improved clinical and MRI outcomes versus SC IFNB-1a in RRMS patients with inadequate response to prior therapy. In a 4-y extension (NCT00930553), patients could receive additional courses of alemtuzumab (12 mg/day on 3 consecutive days; ⩾12 months apart) as needed for disease activity or receive other disease-modifying therapy (DMT) per investigators discretion. Efficacy on clinical/MRI outcomes was maintained through Y6, with 50% receiving no additional alemtuzumab or other DMTs in the extension. Following the initial 4-y extension, patients could continue in TOPAZ (NCT02255656), an additional 5-y extension study, for further evaluation. Objectives: To evaluate 8-y efficacy and safety outcomes in alemtuzumab-treated CARE-MS II patients. Methods: At the investigators discretion, patients in TOPAZ can receive ...
Alemtuzumab is a humanized anti-CD52 antibody licensed for refractory B-cell chronic lymphocytic leukemia (B-CLL), when given intravenously at 30 mg thrice weekly. However, the intravenous route is associated with infusion-related reactions and is inconvenient. We measured blood concentrations in 30 relapsed patients treated with intravenous alemtuzumab and in 20 patients from a previously untreated group who received similar doses subcutaneously. Highest trough samples in the intravenous group were less than 0.5 microg/mL to 18.3 microg/mL (mean 5.4 microg/mL). The cumulative dose required to reach 1.0 microg/mL was 13 mg to 316 mg (mean 90 mg). Higher blood concentrations correlated with the achievement of better clinical responses and minimal residual disease. The highest measured concentrations in the subcutaneous group were similar (0.6 microg/mL to 24.8 microg/mL, mean 5.4 microg/mL). However, the cumulative dose to reach 1.0 microg/mL was higher: 146 mg to 1106 mg (mean 551 mg). No antiglobulin
If they had read our paper…… The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G.Mult Scler Relat Disord. 2020 May 12;43:102174. doi: 10.1016/j.msard.2020.102174. …..They would have known this.. Alemtuzumab is the sledge hammer to MS and it depletes your T and B cells and your MS goes away. So does your protective immune response, at least for a few weeks and this can be seen by the need to use treatments such as Acylovir to reduce viral infections. What happens to you when you get may predict disaster…howeverwe have made the case that the innate immune response is numero uno when it comes to kicking COVID-butt. The clinical experiment will give us the answer and there are a few case reports that support this view and the best one has just surfaced.. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab Eva Fernández-Díaz, Julia ...
The broad use of alemtuzumab in the routine clinical practice setting is feasible and active in unselected patients with pretreated CLL, and the current results confirmed the activity and safety of this agent, as reported in previously published clinical studies.
Recombinant monoclonal antibody manufactured using Recombinant Platform with variable regions from the hybridoma YNB46.1.8 (Campath 9-H) to detect CD4 expression in humans
Official pharmaceutical website with information regarding treatment for B-cell chronic lymphocytic leukemia for patients and health professionals. ...
We show that in the first year the occurrence before the next infusion is very small, although not in the paper I have reasonable evidence that at least one out of about 400 people did not respond well to the second cycle because of this. However if you need a third cycle I suspect the risk of the drug not working well is increased (thirty fold) as and so you need to look at your bloods to ensure the drug is working. Genzyme have the data to know how small that risk is, they need to be open about this and this paper will help in that process. If the drug isnt you need to switch.. Delete ...
We show that in the first year the occurrence before the next infusion is very small, although not in the paper I have reasonable evidence that at least one out of about 400 people did not respond well to the second cycle because of this. However if you need a third cycle I suspect the risk of the drug not working well is increased (thirty fold) as and so you need to look at your bloods to ensure the drug is working. Genzyme have the data to know how small that risk is, they need to be open about this and this paper will help in that process. If the drug isnt you need to switch.. Delete ...
We show that in the first year the occurrence before the next infusion is very small, although not in the paper I have reasonable evidence that at least one out of about 400 people did not respond well to the second cycle because of this. However if you need a third cycle I suspect the risk of the drug not working well is increased (thirty fold) as and so you need to look at your bloods to ensure the drug is working. Genzyme have the data to know how small that risk is, they need to be open about this and this paper will help in that process. If the drug isnt you need to switch.. Delete ...
LEMTRADA®, because of its risks, is generally for relapsing MS patients who have tried 2 or more MS medicines that didnt work well enough.
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Alemtuzumab belongs to the class of medications called selective immunomodulators. It is used to treat adults with relapsing remitting multiple sclerosis (RRMS) who are experiencing an active episode of RRMS and for whom other treatments have not been effective.
高い抗原親和性、特異性と安定した品質を兼ね備えたアブカムのウサギ・モノクローナル抗体 RabMAb® ab109185 交差種: Hu 適用: WB,IP,IHC-P,Flow Cyt,ICC/IF
高い抗原親和性、特異性と安定した品質を兼ね備えたアブカムのウサギ・モノクローナル抗体 RabMAb® ab92741 交差種: Ms,Rat 適用: WB,IHC-P
"Anti-Cathepsin K Antibody (A5871)". online catalog. Ltd. 2018. Retrieved 16 January 2018. Brömme ... 1 February 2013). "A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms". American Journal of Clinical Pathology. ... Cathepsin K antibodies are marketed for research into expression of this enzyme by various cells. Merck had a cathepsin K ... "Cathepsin K Antibodies". Novus Biologicals online catalog. Novus Biologicals, LLC. 2016. Retrieved 2 October 2016. "Anti- ...
The most common neoplasm affecting the thyroid gland is a benign adenoma, usually presenting as a painless mass in the neck. ... These antibodies activate the receptor, leading to development of a goitre and symptoms of hyperthyroidism, such as heat ... Lastly, antibodies against components of the thyroid, particularly anti-TPO and anti-thyroglobulin, can be measured. These may ... Occasionally such antibodies block but do not activate the receptor, leading to symptoms associated with hypothyroidism. In ...
Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies ... Antibody-drug conjugates (ADCs) are antibodies linked to one or more drug molecules. Typically when the ADC meets the target ... Four major antibody types that have been developed are murine, chimeric, humanised and human. Antibodies of each type are ... Initial therapeutic antibodies were murine analogues (suffix -omab). These antibodies have: a short half-life in vivo (due to ...
AT20 cells are BALB/c lymphoma cells derived from spontaneous reticulum cell neoplasm. ATCC TIB-208 cells originated from B- ... A20 cells are also highly responsive to immunomodulatory antibodies, and are therefore used frequently in immunotherapy drug ...
The antibody reactivity was due to a protein never known before, and is chemically responsive to all types of human and ... The protein was identified during investigations on the origin of multiple myeloma, a B-cell hematologic neoplasm. To ... "A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union". Science. 343 (6171): 656-661 ... nonhuman antibodies available. The protein is about 50 kDa in size, and composed of 556 amino acids. Tully, J. G.; Taylor- ...
Monoclonal neoplasm (tumor): A single aberrant cell which has undergone carcinogenesis reproduces itself into a cancerous mass ... Common usages of this term include: Monoclonal antibody: A single hybridoma cell, which by chance includes the appropriate V(D) ... In informal laboratory jargon, the monoclonal antibodies isolated from cell culture supernatants of these hybridoma clones ( ... J recombination to produce the desired antibody, is cloned to produce a large population of identical cells. ...
... serves to be a pan-B cell marker for the detection of B-cell neoplasms. However, tumor cells in some cases of T- ... "Anti-CD79 antibody induces B cell anergy that protects against autoimmunity". Journal of Immunology. 192 (4): 1641-50. doi: ... Other studies that focused on the deficiencies observed in neonatal antibody production can be due to various intrinsic ... lymphoblastic leukemia/lymphoma and AML has shown to potentially react positively with CD79 monoclonal antibodies. In addition ...
These antibodies are transported from the plasma cells by the blood plasma and the lymphatic system to the site of the target ... and plasma cell leukemia are malignant neoplasms ("cancer") of the plasma cells. Multiple myeloma is frequently identified ... LLPC can maintain antibody production for decades or even for the lifetime of an individual, and, unlike B cells, LLPC do not ... Plasmablasts secrete more antibodies than B cells, but less than plasma cells. They divide rapidly and are still capable of ...
... or monoclonal antibody termed Ki-67 can be used for grading of different neoplasms, e.g. astrocytoma. They can be of diagnostic ... PCNA type 1 and type 2 Antibody Patterns". Antibody Retrieved 2008-04-15. Dan Krotz. "Structure of a clamp-loader ... Imaging of the nuclear distribution of PCNA (via antibody labeling) can be used to distinguish between early, mid and late S ... However, an important limitation of antibodies is that cells need to be fixed leading to potential artifacts. On the other hand ...
... the plasmablasts in lymphoid neoplasms with plasmablastic differentiation do not mature into plasma cells or form antibodies ... Lymphoid neoplasms with plasmablastic differentiation were classified by the World Health Organization, 2017 as a sub-grouping ... In cases so infected, the lymphoid neoplasm may result, at least in part, from this viral infection and therefore can be ... The lymphoid neoplasms with plasmacytic differentiation are: 1) Plasmablastic lymphoma: The most common of these lymphoid ...
B lymphocytes kill pathogens by producing antibodies against them, while T lymphocytes directly kill them by engulfing them or ... Squamous cell carcinoma is a type of neoplasm that can affect lingual tonsils. Enlarged or hypertrophic lingual tonsils have ...
... intraepidermal antibodies as well as along the dermoepidermal junction. Patients with low concentration of antibodies only ... in association with an underlying neoplasm". A study concluded in 2009, summarized in 2010, surrounded the surgical removal of ... Demonstration of certain antibodies in the serum was named as the basis for diagnosis of PNP. This piece labeled PNP as a " ... Specifically, antibodies against envoplakin and periplakin were being investigated. Further use of ELISA testing on these ...
Where an underlying neoplasm is the cause, treatment of this condition is indicated in order to reduce progression of symptoms ... If the AAG is paraneoplastic, they have a form of cancer, and their immune system has produced paraneoplastic antibodies in ... Additionally, a blood test showing high levels of the antibody ganglionic nicotenic acetylcholine receptor (gAChr) occur in ... Paola Sandroni & Phillip A. Low (2009). "Other Autonomic Neuropathies Associated with Ganglionic Antibody". Autonomic ...
Using monoclonal antibodies against ALK and NPM1, Falini and colleagues took major steps forward in the biological and clinical ... Falini also contributed to the development over time of modern classifications of lympho-hematopoietic neoplasms, including ... His scientific activity ranges from the field of monoclonal antibodies for diagnostic and therapeutic purposes to genomic ... Falini was a pioneer in the generation of novel monoclonal antibodies directed against oncoproteins involved in the ...
... heterophile antibodies, enterocystoplasties, gestational trophoblastic diseases (GTD), and gestational trophoblastic neoplasms ... In the 1970s, the discovery of monoclonal antibodies led to the development of the relatively simple and cheap immunoassays, ... heterophilic antibody, familial hCG syndrome and cancer. Urine tests can be falsely positive in those that are taking the ... which is due to people having human antianimal or heterophilic antibodies. False positives can also be caused by (in order of ...
... antibodies, neoplasm MeSH D12.776.124.486.485.114.248 - antibodies, phospho-specific MeSH D12.776.124.486.485.114.252 - ... antibodies, neoplasm MeSH D12.776.124.790.651.114.248 - antibodies, phospho-specific MeSH D12.776.124.790.651.114.252 - ... antibodies MeSH D12.776.124.486.485.114.071 - antibodies, anti-idiotypic MeSH D12.776.124.486.485.114.089 - antibodies, ... antibodies, bispecific MeSH D12.776.124.486.485.114.143 - antibodies, blocking MeSH D12.776.124.486.485.114.167 - antibodies, ...
Only one type of light chain is present in a typical antibody, thus the two light chains of an individual antibody are ... with a highly divergent ratio indicative of neoplasm. The quotient of kappa divided by lambda, according to a novel polyclonal ... The immunoglobulin light chain is the small polypeptide subunit of an antibody (immunoglobulin). A typical antibody is composed ... Monoclonal antibody Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA (2001). "Serum reference ...
Monoclonal antibodies against CD44 variants include bivatuzumab for v6. CD44 is a multistructural and multifunctional cell ... On the contrary, in some neoplasms CD44 upregulation is associated with a favorable outcome. This is true of prostate cancer, ... Experiments in animals have shown that targeting of CD44 by antibodies, antisense oligonucleotides, and CD44-soluble proteins ... markedly reduces the malignant activities of various neoplasms, stressing the therapeutic potential of anti-CD44 agents. High ...
A Phase I study of Milatuzumab, a humanized anti-CD74 antibody, and Veltuzumab, a humanized anti-CD20 antibody, in patients ... CD74: a new candidate target for the immunotherapy of B-cell neoplasms. R. Stein, M.J. Mattes, T.M. Cardillo, H.J. Hansen, C.H ... Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. P. Sapra, R. Stein, J ... hLL1-Dox Milatuzumab has been linked to doxorubicin to form an antibody-drug conjugate or ADC (known as hLL1-Dox or IMMU-110) ...
Although chemotherapy and hysterectomy are currently used in a clinical setting, the use of diverse treatments including anti- ...
Another important area where one can talk of "clones" of cells is neoplasms. Many of the tumors derive from one (sufficiently) ... These terms are most commonly used in context of antibodies or immunocytes. This concept of clone assumes importance as all the ... The B cells in the body have two important phenotypes (functional forms)-the antibody secreting, terminally differentiated ( ... "Clonal origin and expansions in neoplasms: biologic and technical aspects must be considered together". The American Journal of ...
By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal ... In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to ... A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer Smith-Jones PM. ... The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells ...
Classification of the antibodies is based on their activity at different temperatures and their etiology. Antibodies with high ... Less common causes of warm-type AIHA include neoplasms other than lymphoid, and infection. Secondary warm type AIHA has been ... Usually, the antibody becomes active when it reaches the limbs, at which point it opsonizes RBCs. When these RBCs return to ... Antibodies are produced against the RBCs, which leads to complement activation. Complement fragments, such as C3a, C4a and C5a ...
The company also advanced other clinical-stage products, including Nimotuzumab, an EGFR-targeting monoclonal antibody, and ... which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and ... YM BioSciences' principal medicine of interest was a monoclonal antibody - Nimotuzumab - targeting the epidermal growth factor ...
Rous, P. (1909-11-01). "Parabiosis as a test for circulating anti-bodies in cancer: First paper". The Journal of Experimental ... Rous, Peyton (1910-09-01). "A transmissible avian neoplasm.(Sarcoma of the common fowl.)". Journal of Experimental Medicine. 12 ... Noyes, W. F.; Mellors, R. C. (1957-10-01). "Fluorescent antibody detection of the antigens of the Shope papilloma virus in ... that the neoplasm will differ from the better-known tumors of mammals." He continued to maintain and transplant the tumor in ...
Development of murine neoplasms started with work with the BALB/c mice to isolate the IgG1 secreting MOPC21 tumor. From this ... Several therapeutic antibody products are produced using the NS0 cell line including daclizumab and eculizumab. Barnes, LM; ... Galfrè, G; Milstein, C (1981). "Preparation of monoclonal antibodies: strategies and procedures". Methods in Enzymology. 73 (Pt ... NSo cells are naturally antibody-producing suspension cells with a lymphoblast morphology. Gene amplification is typically ...
Quantitative analysis of antibody localization in human metastatic colon cancer: A phase I study with monoclonal antibody A33. ... Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810-11813. ... Of the monoclonal antibodies developed in Dr. Old's laboratory, thirteen have been licensed and seven are in clinical trials. ... the anti-EGFr antibody Hu806, which Abbott Laboratories acquired exclusive world-wide rights to develop in a major licensing ...
Monoclonal antibodies e.g. rituximab (anti-CD20) and eculizumab (anti-C5) have been used but the therapeutic benefits are ... as well as hematological malignancies including non-Hodgkin lymphoma and myeloproliferative neoplasms. The exact pathogenesis ... As a weak, biphasic antibody, it absorbs to the P antigen in the cold temperature as in the periphery in the primary phase, and ... Autoimmune hemolytic anemia Warm-antibody type Primary Secondary (lymphoproliferative disorders, autoimmune disorders): 259 ...
All women generated antibodies against hCG, but only 119 (80%) generated antibody titers clearly above 50 ng/mL, which was the ... hCG was discovered to be expressed in certain kinds of malignant neoplasms, including breast cancer, adenocarcinoma of the ... In passive immunity the desired antibody titers are achieved by injecting antibodies directly into an animal. The efficacy of ... anti-sperm antibodies are not likely to have adverse health effects, since anti-sperm antibodies are produced by up to 70% of ...
... monoclonal antibody - monoclonal antibody 3F8 - monocyte - Montanide ISA-51 - Morinda citrifolia - morphology - motexafin ... neoplasm - nephrotomogram - nephrotoxic - nephroureterectomy - nerve block - nerve grafting - nerve-sparing radical ... bispecific antibody - bispecific monoclonal antibody - bisphosphonate - bizelesin - BL22 immunotoxin - black cohosh - black ... antibody - antibody therapy - anticachexia - anticancer antibiotic - anticarcinogenic - anticoagulant - anticonvulsant - ...
The World Health Organization (2019) classified papillary neoplasms (i.e. benign or cancerous tumors) of the breast into 5 ... cytokeratin 5/6 antibodies that detect two markers of myoepithelial cells, cytokeratin 5 and keratin 6A); 3) the presence of a ... Brogi E, Krystel-Whittemore M (January 2021). "Papillary neoplasms of the breast including upgrade rates and management of ... Tay TK, Tan PH (June 2021). "Papillary neoplasms of the breast-reviewing the spectrum". Modern Pathology. 34 (6): 1044-1061. ...
Cohen syndrome Colavita-Kozlowski syndrome Cold abscess Cold agglutination syndrome Cold agglutinin disease Cold antibody ... Carrington syndrome Cartilage hair hypoplasia like syndrome Cartilage-hair hypoplasia Cartilaginous neoplasms Cartwright-Nelson ... hypoxia Cerebral malformations hypertrichosis claw hands Cerebral palsy Cerebral thrombosis Cerebral ventricle neoplasms ... Choriocarcinoma Chorioretinitis Chorioretinopathy dominant form microcephaly Choroid plexus cyst Choroid plexus neoplasms ...
It is characterized by having high levels of a circulating antibody, immunoglobulin M (IgM), which is made and secreted by the ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... Treatment includes the monoclonal antibody rituximab, sometimes in combination with chemotherapeutic drugs such as chlorambucil ... Hematologic malignant neoplasms, Lymphoma, Rare cancers, Vascular-related cutaneous conditions). ...
... neoplasm protein - Nernst equation - nerve - nerve growth factor - nerve growth factor receptor - nerve tissue protein - nerve ... antibody - apoenzyme - apolipoprotein - apoptosis - aquaporin - archaea - arginine - argipressin - aromatic amine - aromatic ... monoclonal antibody - monomer - monosaccharide - monosaccharide transport protein - morphogenesis - morphogenetic field - mos ...
The efficacy of rituximab in CD- PEL may be due to the ability of this antibody to kill non-malignant CD+ 20 lymphocytes and ... This lymphoma also belongs to a group of lymphoid neoplasms with plasmablastic differentiation that involve malignant ... Rituximab, a monoclonal antibody directed against and killing CD20-expressing cells, appears to improve the efficacy of ... One factor that appears to improve the treatment of Type II PEL is the addition of rituximab (a monoclonal antibody directed ...
It has a chimeric monoclonal antibody (cAC10) that binds to the membrane protein CD30. This binding delivers monomethyl ... "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375-2390. doi: ... "The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications". Blood. 117 (19): ...
However, the presence of both the CD79a and CD79b ITAM tyrosines were required for normal T cell dependent antibody responses. ... and is also present in virtually all B-cell neoplasms, including B-cell lymphomas, plasmacytomas, and myelomas. It is also ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... Approaches include antibodies, checkpoint therapy, and adoptive cell transfer. Laser therapy uses high-intensity light to treat ...
Kales SC, Ryan PE, Nau MM, Lipkowitz S (June 2010). "Cbl and human myeloid neoplasms: the Cbl oncogene comes of age". Cancer ... Immunohistochemistry using antibodies to ubiquitin can identify abnormal accumulations of this protein inside cells, indicating ... "DNA copy number losses in human neoplasms". The American Journal of Pathology. 155 (3): 683-94. doi:10.1016/S0002-9440(10)65166 ...
2006). "Rearrangement of only one human IGHV gene is sufficient to generate a wide repertoire of antigen specific antibody ... IGHV is the immunoglobulin heavy chain variable region genes; in B-cell neoplasms like chronic lymphocytic leukemia, mutations ... "Nucleotidic sequence analysis of the variable domains of four human monoclonal IgM with an antibody activity to myelin- ...
In practice, this is inferred by the detection of only one of the mutually exclusive antibody light chains, kappa or lambda, on ... Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the ... Normal B lymphocytes consist of a stew of different antibody-producing cells, resulting in a mixture of both kappa- and lambda- ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ...
Pussinen PJ, Alfthan G, Rissanen H, Reunanen A, Asikainen S, Knekt P (September 2004). "Antibodies to periodontal pathogens and ... induced Genetic/developmental disorders Specific infections Inflammatory and immune conditions Reactive processes Neoplasms ... Pussinen PJ, Alfthan G, Tuomilehto J, Asikainen S, Jousilahti P (October 2004). "High serum antibody levels to Porphyromonas ... suppression of antibody production, and the reduction of phagocytosis by neutrophils Ehlers-Danlos syndrome and Papillon- ...
Articles with short description, Short description is different from Wikidata, Epidermal nevi, neoplasms, and cysts, Conditions ... a monoclonal antibody that neutralizes tumor necrosis factor alpha). Both of these individuals showed slowly developing, modest ... Trichofolliculoma Spiradenoma spiradenocarcinoma List of cutaneous conditions List of cutaneous neoplasms associated with ... "Treatment of multiple familial trichoepitheliomas with a combination of aspirin and a neutralizing antibody to tumor necrosis ...
Targeting can also be achieved by attaching the radioisotope to another molecule or antibody to guide it to the target tissue. ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... which is a combination of an iodine-131 labelled and an unlabelled anti-CD20 monoclonal antibody. These medications were the ... which is an anti-CD20 monoclonal antibody conjugated to yttrium-90. In 2003, the FDA approved the tositumomab/iodine (131I) ...
Within this list, the term immunoglobulin is abbreviated to Ig when used as a prefix to a specific antibody isotype (i.e. IgA, ... neoplasms, and cysts are skin lesions that develop from the epidermal layer of the skin. Aberrant basal cell carcinoma ... an overview with emphasis on the myeloid neoplasms". Chem. Biol. Interact. 184 (1-2): 16-20. doi:10.1016/j.cbi.2009.10.009. ... neoplasms invading or aberrantly present in the dermis. Acquired progressive lymphangioma (benign lymphangioendothelioma) Acral ...
Furthermore, antibodies against the retrovirus was identified in gibbons without evidence of disease which suggests a natural ... Gibbon-ape leukemia virus (GaLV) is an oncogenic, type C retrovirus that has been isolated from primate neoplasms, including ... Olagoke, O.; Quigley, B. L.; Eiden, M. V.; Timms, P. (2019-08-27). "Antibody response against koala retrovirus (KoRV) in koalas ... The virus was identified as the etiological agent of hematopoietic neoplasms, leukemias, and immune deficiencies within gibbons ...
When DNA is released via apoptosis of an infected host cell, antibodies are produced against the host's own DNA. (see ... Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of myeloid cancer in which malignant pDCs infiltrate the ... pDCs that undergo malignant transformation cause a rare hematologic disorder, blastic plasmacytoid dendritic cell neoplasm. In ...
The cDNA is sequenced and the sequence encoding the variable heavy and variable light chains of these antibodies are cloned ... May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ... In this therapy, mice are immunized with the CD19 antigen and produce anti-CD19 antibodies. Hybridomas developed from mouse ... An extensive panel of monoclonal antibodies to cell surface markers, particularly CD or cluster of differentiation markers, are ...
Jaffe and her fellow NCI researchers showed that red blood cells coated with antibody and erythrocyte-antibody-complement (EAC ... of the Society of Hematopathology at the time that the WHO's Revised European-American Classification of Lymphoid Neoplasms ( ...
"Humanization" of these antibodies (genetically transforming them to be as similar to a human antibody as possible) has allowed ... A study of 93 patients with incurable neoplasms". J Natl Med Assoc. 43 (4): 211-240. PMC 2616951. PMID 14850976. Li, MC; Hertz ... Although monoclonal antibodies (immune proteins which can be selected to precisely bind to almost any target) have been around ... Another branch in targeted therapy is the increasing use of monoclonal antibodies in cancer therapy. ...
This continuous signaling, it is presumed, leads to the development of myeloid and/or lymphoid neoplasms that commonly include ... For instance, forcing PDGFRβ into close proximity of each other by overexpression or with antibodies directed against the ... PDGFRB-ETV6 fusion protein-induced neoplasms often present with features that would classify them as Chronic myelomonocytic ... These patients, unlike many patients with similarly appearing neoplasms, respond well to the tyrosine kinase inhibitor, ...
Rituximab, the anti-CD20 chimeric antibody, is a key component of therapy. Responses vary from 55% to 77% with monotherapy and ... ISBN 0-7817-5007-5. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ...
Laryngeal neoplasms Abnormal growths in the larynx (voice box) that can be cancerous or noncancerous. Laryngeal nodules ... Autoimmune deafness Individual's immune system produces abnormal antibodies that react against the body's healthy tissues. ...
SeV antibodies that cross-reactive with HPIV-1 antibodies are present in most people, however, majority of people do not have ... Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal ... Instead, it can be measured using anti-glycan antibodies, and despite the large collection of such antibodies in a community ... and from (No. ABIN6737444) . Monoclonal antibodies (IgG1) to F-protein are available from Kerafast ( ...
Rituximab is a commercial monoclonal antibody that binds to the CD20 cell surface protein on B-cells to thereby target these ... An Indolent Neoplasm With Features Distinct From Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation". The ... to immunotherapy with either one of these monoclonal antibodies. A phase I clinical trial is recruiting individuals to study ...
They can also include the administration of laboratory-produced antibodies specific to tumor antigens to create or boost an ... a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study ... Vaccines can deliver various tumor-associated factors (tumor antigens) to the immune system, resulting in a natural antibody ...
June 2001). "Expression of anti-OV6 antibody and anti-N-CAM antibody along the biliary line of normal and diseased human livers ... Misago N, Narisawa Y (September 2006). "Cytokeratin 15 expression in neoplasms with sebaceous differentiation". Journal of ... ALDH alkaline phosphatase alpha6-integrin Anti-WNT2B monoclonal antibody antithrombin III (AT) asialo GM1 Bcl-2 Beta- ...
... antibodies, neoplasm MeSH D12.776.377.715.548.114.248 - antibodies, phospho-specific MeSH D12.776.377.715.548.114.252 - ... antibodies MeSH D12.776.377.715.548.114.071 - antibodies, anti-idiotypic MeSH D12.776.377.715.548.114.107 - antibodies, ... antibodies, bispecific MeSH D12.776.377.715.548.114.143 - antibodies, blocking MeSH D12.776.377.715.548.114.167 - antibodies, ... antibodies, helminth MeSH D12.776.377.715.548.114.191 - antibodies, heterophile MeSH D12.776.377.715.548.114.224 - antibodies, ...
These 32 individuals and 64 matched controls were analyzed for serum antibodies indicative of past infection with Chlamydia ... antibodies to C. trachomatis showed the strongest association with cervical cancer (odds ratio = 5.0 (95% confidence interval ... Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. ... Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. ...
This Neoplasms and Solid Tumor study at UCSF is now recruiting people ages 18 years and up. ... Neoplasms, Metastatic solid tumors, Advanced solid tumors, anti-PD-1, TSR-042, Immunotherapy, PD-1, Endometrial, Non-small cell ... A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced ... Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid ...
The monoclonal antibody NCL-CK13 was studied in specimens of craniopharyngioma, ameloblastoma and calcifying odontogenic cyst ... CK13 in craniopharyngioma versus related odontogenic neoplasms and human enamel organ. El Sissy, N.A.. ... This suggests that these neoplasms might have their histogenesis from early stage epithelium, the oral part of the dental ... The neoplastic epithelia of the neoplasms revealed a clear phenotypic and immunohistochemical reactive relationship to the ...
Antibodies, Monoclonal / therapeutic use* * Antibodies, Monoclonal, Humanized * Antibodies, Neoplasm / therapeutic use* * ... insights have been made into the nature of autoimmunity in general based on the clinical response to this monoclonal antibody. ...
Neoplasms Malignant Drug: AK112 Phase 1 Study Design. Go to Top of Page Study Description Study Design Arms and Interventions ... A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors. The safety and scientific validity of this study ... anti-PD-1/VEGF bispecific antibody. immunotherapy. immuno-oncology. advanced solid tumors. bispecific. PD-1/VEGF. ... Number of subjects who develop detectable anti-drug antibodies (ADAs) [ Time Frame: From first dose of AK112 through 90 days ...
Neoplasms by Site. Neoplasms by Histologic Type. Genital Neoplasms, Female. Urogenital Neoplasms. Uterine Neoplasms. Uterine ... Known severe (Grade ≥ 3) hypersensitivity reactions to fully human monoclonal antibodies, antibody, or severe reaction to ... Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer. The safety and scientific validity of this study is the ... Anti-drug Antibodies (ADAs) [ Time Frame: First study dose (pre-dose) through 3 months following last study dose (up to 2 years ...
Antibodies, Viral, Antibodies, Neutralizing, COVID-19, SARS Virus, Immunogenicity, Vaccine and Neoplasms. ... 27. Van Oekelen O, Gleason CR, and Agte S, et al (2021) Highly variable SARS-CoV-2 spike antibody responses to two doses of ... 38. Lim SH, Campbell N, and Johnson M, et al (2021) Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma ... 23. Palich R, Veyri M, and Vozy A, et al (2021) High seroconversion rate but low antibody titers after two injections of ...
Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med. 1982 Jun. 72(6): ... Warm-cold antibody combinations. Hemolysis due to cold agglutinins can sometimes be accompanied by a warm antibody (IgG), ... In mixed antibody syndromes, the IgG and IgM antibody components can be separated. The cold autoantibodies reactive at ... Uncommonly, the antibody may be directed against only the i antigen found on fetal cord blood RBCs, which lack the mature I ...
Neoplasms of the liver. New York: Springer-Verlag, 1987:189-97. 10. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, ... Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and cirrhosis. Lancet 1989;2: ... Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-8. 13. ...
A BW smear was labeled with genus-specific fluorescein isothiocyanate-conjugated antibodies (indirect fluorescent antibody ... Cryptosporidium baileyi Pulmonary Infection in Immunocompetent Woman with Benign Neoplasm On This Page ... Findings from a 51-year-old immunocompetent woman with a benign neoplasm and Cryptosporidium baileyi pulmonary infection, ... Cryptosporidium baileyi Pulmonary Infection in Immunocompetent Woman with Benign Neoplasm. Emerging Infectious Diseases. 2020; ...
Anti-TPO: anti-thyroid peroxidase antibody; Anti-Tg: anti-thyroglobulin antibody; TIRADS: Thyroid Imaging Reporting and Data ... follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), suspicious for malignancy and malignant according to Bethesda ... follicular neoplasm/suspicious for follicular neoplasm; PTC: papillary thyroid cancer. ... follicular neoplasm/suspicious for follicular neoplasm; PTC: papillary thyroid cancer ...
Neoplasms, Plasma Cell. Smoldering Multiple Myeloma. Neoplasms by Histologic Type. Neoplasms. Hemostatic Disorders. Vascular ... Patients with antiviral therapy for HCV started before initiation of IMP and positive HCV antibodies are eligible. The ... Number of participants with anti-drug antibodies against isatuximab. *Sustained MRD negativity [ Time Frame: Up to ... Immunogenicity: Incidence of anti-drug antibodies (ADA) [ Time Frame: Up to approximately 24 months ]. ...
In general, lymphomas are divided into 2 large groups of neoplasms, namely non-Hodgkin lymphoma (NHL) and Hodgkin disease. ... Antineoplastics, Anti-CD19 Monoclonal Antibodies. Class Summary. The monoclonal antibody binds to human CD19, a transmembrane ... A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood ... Monoclonal Antibodies. Class Summary. The agents in this class target specific antigens in carcinoma cells and induce ...
Lung Neoplasms. *ONCOGENES. *Antibodies, Monoclonal. *Pathology Department, Hospital. *IMMUNOHISTOCHEMISTRY. Data availability ...
... fluorescent antibody technique; humans; lung neoplasms; mechanism of action; models; morbidity; phosphorylation; proteome; ... esophageal neoplasms; glutamine; human health; liver neoplasms; neoplasm cells; pH; pancreatic neoplasms; pollution; research; ... antineoplastic activity; antineoplastic agents; biosynthesis; breast neoplasms; colorectal neoplasms; humans; lung neoplasms; ... lung neoplasms; neoplasm cells. Abstract:. ... In this study, a series of novel naphthalimide-benzotriazole conjugates (1a-3c) ...
... high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. ... at Kings College London since August 2022 and continues to study the immunobiology of Myeloid Malignancies and Neoplasms. His ...
Kidney Neoplasms; Logistic Models; Male; Models, Biological; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Outcome ... Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; ...
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected ... of memory precursor cd8 t cells in regressing tumors following combination therapy with vaccine and anti-pd-1 antibody. ... by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody ...
Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med. 1982 Jun. 72(6): ... Warm-cold antibody combinations. Hemolysis due to cold agglutinins can sometimes be accompanied by a warm antibody (IgG), ... In mixed antibody syndromes, the IgG and IgM antibody components can be separated. The cold autoantibodies reactive at ... Uncommonly, the antibody may be directed against only the i antigen found on fetal cord blood RBCs, which lack the mature I ...
A, JAK2 V617F and WT HUVEC lysates were subjected to SDS-PAGE and immunoblotted with anti-JAK2 and anti-GAPDH antibodies. B, ... Myeloproliferative neoplasms (MPN) are disorders of the bone marrow characterized by excess clonal hematopoiesis resulting in ... A, JAK2 V617F and WT HUVEC lysates were subjected to SDS-PAGE and immunoblotted with anti-JAK2 and anti-GAPDH antibodies. B, ... The following antibodies were used: mouse monoclonal anti-PDI (RL77; Abcam Cat#ab5484, RRID:AB_304927), rabbit polyclonal anti- ...
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast ...
Among 7 patients, no neoplasms were identified. ANNA1 = antineuronal nuclear antibody type 1 (anti-Hu); ANNA3 = antineuronal ... onconeural antibodies, n = 19; unclassified antibodies, n = 3; no antibodies, n = 3). Paraneoplastic myeloneuropathies had ... microtubule-associated protein 1B antibody; mRS=. modified Rankin Scale; PCA=. Purkinje cell cytoplasmic antibody. ... Figure 1 Cancer and Onconeural Antibody Associations. (A) Summary of onconeural antibodies and presence of cancer; 3 patients ...
Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. American journal of ... Serum antibodies to C. trachomatis were associated with an increased risk for CIN [odds ratio (OR) = 7.3; 95% confidence ... Table 1 Association between CIN with the presence of IgG antibodies to Chlamydia trachomatis or inclusion bodies of C. ... The prevalence of serum antibodies positive for C. trachomatis was 22 (41%) for CINI, 3 (100%) for CINII and 2 (66%) for CINIII ...
The monoclonal antibody NCL-CK13 was studied in specimens of craniopharyngioma, ameloblastoma and calcifying odontogenic cyst ... neoplasms and the mandible and maxillae of normal human fetuses. There was a decrease in NCL-CK13 ... ...
Neoplasm Antibodies Medicine & Life Sciences 29% * Polymerase Chain Reaction Medicine & Life Sciences 25% ... Methods: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti DMBT1 antibody (DMBTh12) and sections ... Methods: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti DMBT1 antibody (DMBTh12) and sections ... Methods: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti DMBT1 antibody (DMBTh12) and sections ...
Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence ... These neoplasms predominantly had epithelial origin, with overexpressing the Epidermal Growth Factor Receptor (EGFR) in a high ... due to its capacity to develop anti EGF antibodies able to reduce circulating EGF concentrations by increasing the antibody ... Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence, ...
... such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasms, ... or antibody avidity. Studies were excluded if they lacked a comparison group in which efficacy of 3 doses of HPV vaccine ... Because antibody kinetics are similar with 2-dose and 3-dose series, duration of protection is also expected to be long-lasting ...
MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma. ... "Bile Duct Neoplasms" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... This graph shows the total number of publications written about "Bile Duct Neoplasms" by people in Harvard Catalyst Profiles by ... Below are the most recent publications written about "Bile Duct Neoplasms" by people in Profiles. ...
It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity. ... used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity. ...
Neoplasms of the liver. New York: Springer-Verlag, 1987:189-97. * Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze ... Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and cirrhosis. Lancet 1989;2: ... Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-8. * ...
  • The monoclonal antibody NCL-CK13 was studied in specimens of craniopharyngioma, ameloblastoma and calcifying odontogenic cyst neoplasms and the mandible and maxillae of normal human fetuses. (
  • Campath(®), Genzyme, MA, USA) has recently been investigated in a Phase II clinical trial in the treatment of relapsing-remitting MS. The results observed in the study are very encouraging and multiple insights have been made into the nature of autoimmunity in general based on the clinical response to this monoclonal antibody. (
  • Cold agglutinins commonly have variable heavy-chain regions encoded by VH, with a distinct idiotype identified by the 9G4 rat murine monoclonal antibody. (
  • Red: PE-labeled Cyclin D1 Monoclonal Antibody (SPM587). (
  • When unlabeled antibody is used the cells are further incubated with a labeled antibody against the monoclonal antibody and the presence of labeled ternary immune complexes on the cells is read. (
  • As used herein the term "monoclonal antibody" means an antibody composition having a homogeneous antibody population. (
  • CINQAIR (reslizumab) Injection is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype. (
  • TNFSF14 can be a cytokine neutralization target during novel coronavirus infection, and anti-TNFSF14 monoclonal antibody treatment can reduce the risk of respiratory failure and mortality. (
  • The prognosis of HER2-positive breast cancer has dramatically improved because of introduction of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2. (
  • The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). (
  • Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human tumour necrosis factor (TNF).Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. (
  • Cold agglutinin disease usually results from the production of a specific IgM antibody directed against the I/i antigens (precursors of the ABH and Lewis blood group substances) on red blood cells (RBCs). (
  • Since the mid-1970s, there have been numerous reports of murine monoclonal antibodies that interact with human breast cancer associated antigens. (
  • They can also exhibit antibodies to antigens associated with pemphigus vulgaris (desmoglein 3, 130-kd) and pemphigus foliaceus (desmoglein 1, 160-kd), as well as several others, including epiplakin. (
  • This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. (
  • On the other hand, the CIMAvax EGE vaccine has shown therapeutic efficacy in patients with non-small cell lung tumors (NSCLC) [7], due to its capacity to develop anti EGF antibodies able to reduce circulating EGF concentrations by increasing the antibody titer in treated patients. (
  • Primary ovarian mucinous tumors represent a heterogeneous group of neoplasms, and their diagnosis may be challenging. (
  • KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors. (
  • The antibody in this study binds to certain types of cancer tumors. (
  • Results consistent with neoplasm may prompt fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) testing for BCR-ABL or Jak 2 . (
  • Methods: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti DMBT1 antibody (DMBTh12) and sections from 36 samples, were double-stained also with anti MCM5, one of the 6 pre-replicative complex proteins with cell proliferation-licensing functions. (
  • Proteins were visualized using chemiluminescence detection by incubation with HRP Goat anti-Mouse secondary antibody (Cat. (
  • Dr. Binder studies the epigenetic determinants of gene expression in chronic myeloid neoplasms associated with mutations in the chromatin-remodeling proteins such as ASXL1. (
  • Plasma cells help your body fight infection by producing proteins called antibodies . (
  • Antibodies are proteins normally made by the immune system that bind to substances that don't belong in the body to prevent harm. (
  • Flow Cytometry: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Flow Cytometric analysis of human Cyclin D1 on MCF-7 cells. (
  • Flow Cytometry: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Flow Cytometric analysis of human Cyclin D1 on Jurkat cells. (
  • It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity. (
  • Although there are reports of some studies with anti EGFR monoclonal antibodies (mAbs) in this indication, in advanced stages, the results have not been as expected. (
  • The clinical presentation that corresponds with PCA-Tr antibodies includes paraneoplastic cerebellar degeneration (PCD) and limbic encephalopathy (LE). (
  • Hematologic malignancies are most commonly associated with paraneoplastic pemphigus, although it can also be associated with carcinomas, sarcomas, and benign neoplasms. (
  • Paraneoplastic pemphigus is an autoimmune disorder initiated by an underlying neoplasm. (
  • Passive transfer of paraneoplastic pemphigus sera causes blistering in neonatal mice, proving that the antibodies present are pathogenic. (
  • Immunohistochemistry-Paraffin: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Formalin-paraffin human Mantle Cell Lymphoma stained with Cyclin D1 Ab (Clone SPM587). (
  • The immunohistochemistry technique was performed by the streptavidin-biotin method using the antibody anti-MMP9. (
  • CD45 belongs to a leukocyte common antigen (LCA antibody) family of glycoproteins with molecular weights of 180, 190, 205 and 220 kDa. (
  • Leukocyte common antigen-a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization. (
  • 4. Negative human immunodeficiency virus (HIV) antibody screen, seronegative for hepatitis B surface antigen (HBsAg) and hepatitis C antibody (following HIV and hepatitis testing, subjects will be provided with counseling and referral for health care if any test is positive). (
  • Using this staining technique, fluorescent dye is attached to the known antibodies that correspond to the suspected antigen, in this case, the leukemia cells. (
  • These antibodies will in turn attach to the antigen molecules on the cell surfaces, and if present, will fluoresce when viewed with a fluorescent light. (
  • In collaboration with Mrinal S. Patnaik, M.B.B.S. , he investigates the suitability of cis-regulatory elements to serve as therapeutic targets in high-risk myeloid neoplasms. (
  • More particularly it concerns murine monoclonal anti-human breast cancer antibodies, hybridomas that produce those antibodies, immunochemicals made from those antibodies, and diagnostic and therapeutic methods that use those immunochemicals. (
  • Thromboembolic events (TE) are the most common complications of myeloproliferative neoplasms (MPN). (
  • Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence, principally from epithelial origen. (
  • Cervical uterine cancer represents the fourth malignant neoplasm with the highest incidence in the world in women with 569,847 in 2018. (
  • Those precancerous lesions, according to WHO definition, are morphological lesions, related to increased risk of malignant neoplasm to occur. (
  • Given these results, the authors discuss the difficulty in diagnosing differentiation from a primary or metastatic neoplasm of the scalp, with the resources currently available, until the conclusion that it was a primary carcinoma of the sweat gland. (
  • Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. (
  • Findings from a 51-year-old immunocompetent woman with a benign neoplasm and Cryptosporidium baileyi pulmonary infection, Poland, 2015. (
  • Purkinje cell cytoplasmic-Tr (PCA-Tr) antibodies are associated with Hodgkin's lymphoma. (
  • As for a new umbrella category of PTCL, nodal peripheral T-cell lymphoma with T-follicular helper phenotype (NPTCL-TFH) was firstly classified in the 2017 revision of the World Health Organization (WHO) classification of hematolymphoid neoplasms. (
  • In collaboration with Shaji Kumar, M.D. , he studies the gene expression patterns and chromatin structure of multiple myeloma resistant to immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies. (
  • Immunofluorescence analysis of paraformaldehyde-fixed HeLa, using Fibronectin (GTX112794) antibody at 1:200 dilution. (
  • Fibronectin antibody [N1N2], N-term (GTX112794) dilution: 1:500. (
  • Various lysates were subjected to SDS PAGE followed by western blot with 17785-1-AP (Synaptophysin antibody) at dilution of 1:40000 incubated at room temperature for 1.5 hours. (
  • Immunohistochemical analysis of paraffin-embedded mouse brain tissue slide using 17785-1-AP (Synaptophysin antibody) at dilution of 1:2000 (under 10x lens). (
  • Immunohistochemical analysis of paraffin-embedded mouse brain tissue slide using 17785-1-AP (Synaptophysin antibody) at dilution of 1:2000 (under 40x lens). (
  • Optimal dilution of this antibody should be experimentally determined. (
  • His translational research in multiple myeloma and chronic myeloid neoplasms is concerned with the effects of chromatin remodeling on gene expression in cancer cells. (
  • PDQ plasma cell neoplasms (including multiple myeloma) treatment. (
  • Several studies that evaluated antibody response to COVID-19 vaccination found that patients with solid malignancies had lower serologic response rates compared to healthy controls, but better than patients with haematologic malignancies, who had the lowest seroconversion rates and antibody titres. (
  • Immunogenicity outcomes of interest were seroconversion, geometric mean titers (GMTs), or antibody avidity. (
  • 2019). Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium. (
  • TNF)-alpha inhibitors (etanercept), interleukin-1 (IL-1) blocking agents and other monoclonal antibodies targeting immune cells (e.g., rituximab, alemtuzumab, etc), etc. (
  • Total lysates (15 µg protein) from HeLa (Low expression negative control) and PC-3 (Positive control) were resolved by electrophoresis (4-20% Tris-glycine gel), transferred to nitrocellulose, and probed with 1:500 (1 µg/ml) purified anti-Nestin antibody, clone 10C2. (
  • Fibronectin antibody recognizes fibronectin protein, which is an extracellular glycoprotein (predicted molecular weight of 272 kDa) that exists in two forms. (
  • Fibronectin antibody [N1N2], N-term immunoprecipitates Fibronectin protein in IP experiments. (
  • IP Sample: HeLa whole cell lysate/extract A : 30 μg whole cell lysate/extract of Fibronectin protein expressing HeLa cells B : Control with 3 μg of pre-immune rabbit IgG C : Immunoprecipitation of Fibronectin by 3 μg of Fibronectin antibody [N1N2], N-term (GTX112794) 5% SDS-PAGE The immunoprecipitated Fibronectin protein was detected by Fibronectin antibody [N1N2], N-term (GTX112794) diluted at 1 : 1000. (
  • Fibronectin antibody [N1N2], N-term detects FN1 protein at cytosol on human hepatoma by immunohistochemical analysis. (
  • Fibronectin antibody detects Fibronectin protein by Western blot analysis. (
  • Western Blot: Cyclin D1 Antibody (SPM587) [NBP2-32840] - HELLS expression and protein levels are modulated with YAP1/TEAD inhibition downstream of SHH signaling. (
  • In this manuscript, we describe the immunohistochemical evaluation of the mesothelioma TMA with three key antibodies that are used in making the diagnosis of mesothelioma, and compared the immunohistochemical assessment between manual scoring and image analysis. (
  • This is a unique case due to the low frequency 2 , the atypical clinical history, but mainly the difficult histopathological differential diagnosis and immunohistochemical evaluation among these neoplasms. (
  • These assays involve incubating the cells with the monoclonal antibodies or labeled derivatives thereof. (
  • DESIGN, SETTING, AND PARTICIPANTS: Four serial histologic sections from 90 archival non-small cell lung cancers from January 1, 2008, to December 31, 2010, were distributed to 3 sites that performed the following immunohistochemical assays: 28-8 antibody on the Dako Link 48 platform, 22c3 antibody on the Dako Link 48 platform, SP142 antibody on the Ventana Benchmark platform, and E1L3N antibody on the Leica Bond platform. (
  • A new study available on the pre-print server medRxiv* aims to assess the specificity of the serological assays of SARS-CoV-2 antibodies among patients known to have a tissue-borne parasitic infection or those who reside in areas where the virus is endemic. (
  • After adjustment for smoking and other sexually transmitted diseases, antibodies to C. trachomatis showed the strongest association with cervical cancer (odds ratio = 5.0 (95% confidence interval 1.6-15.7)), but the numbers were too small for drawing conclusions as to the sexually transmitted diseases with which cervical cancer is most specifically associated. (
  • Methods Observational study investigating patients with myeloneuropathy and underlying cancer or onconeural antibody seropositivity. (
  • Western Blot: Cyclin D1 Antibody (SPM587) [NBP2-32840] - analysis of Cyclin D1 in human breast cancer cell line MDA-MB-231 cell lysate using anti-Cyclin D1. (
  • Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described. (
  • Another aspect of the invention concerns labeled derivatives of the above described monoclonal antibodies that are labeled with a detectable label that permits the derivatives to be used in diagnosing or monitoring human breast cancer. (
  • Monoclonal antibodies and cancer therapy : proceedings of the Roche-UCLA Symposium, held in Park City, Utah, January 26-February 2, 1985 / editors, Ralph A. Reisfeld, Stewart Sell. (
  • This is an open label single-arm phase II study to evaluate the combination therapy of the antibody drug conjugate, sacituzumab govitecan, and the anti-PD-L1 antibody, atezolizumab, in patients with triple negative breast cancer . (
  • Plasmapheresis is effective because the autoantibodies, which are most often IgM, are loosely bound to the erythrocytes, and IgM antibodies are incapable of diffusing into the extravascular space. (
  • Another autoimmune hemolytic anemia syndrome associated with cold-reacting autoantibodies is paroxysmal cold hemoglobinuria , which involves the IgG Donath-Landsteiner (D-L) antibody. (
  • Statistical analyses were performed from December 1, 2015, to August 30, 2016, to compare antibodies and pathologists' scoring of tumor and immune cells. (
  • CONCLUSIONS AND RELEVANCE: The assay using the SP142 antibody is an outlier that detected significantly less PD-L1 expression in tumor cells and immune cells. (
  • The pathologists showed excellent concordance when scoring tumor cells stained with any antibody but poor concordance for scoring immune cells stained with any antibody. (
  • Convalescent plasma may be beneficial in COVID-19 patients with B-cell neoplasm who are unable to mount a humoral immune response. (
  • NG-641 is an oncolytic adenoviral vector which expresses a FAP-TAc antibody together with an immune enhancer module (CXCL9/CXCL10/IFNα). (
  • The antibodies that attack the neural tissue develop in response to tumor cells. (
  • In addition, several biological therapies are currently available for these patients, including interferons, rituximab, and radiolabeled antibodies (the newest biological therapy). (
  • These 32 individuals and 64 matched controls were analyzed for serum antibodies indicative of past infection with Chlamydia trachomatis, Neisseria gonorrhoeae, cytomegalovirus, Epstein-Barr virus, and herpes simplex virus type 2. (
  • 1) Background: A reliable non-invasive distinction between low- and high-risk pancreatic intraductal papillary mucinous neoplasms (IPMN) is needed to effectively detect IPMN with malignant potential. (
  • 2020). A molecular map of lung neuroendocrine neoplasms. (
  • Zhai Y, Zhong Z, Zariffard M, Spear GT, Qiao L. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies. (
  • The first study investigating tissue‐specific antibodies in the human prostate can be traced back to 1969 by Ablin et al. (
  • Cyclin D1, one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. (
  • A study of 735 hematopoietic and nonhematopoietic human neoplasms. (
  • Then the cells were intracellularly stained with 2 µg/mL anti-Nestin Antibody (10C2) and followed by DyLight™ 594 goat anti-mouse IgG (red) for 1 hour at room temperature. (
  • Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. (
  • Substituting a pyridine ring for a benzene ring in the acylation agent N-succinimidyl 3-iodobenzoate has resulted in a useful approach for the radiohalogenation of monoclonal antibodies, peptides, and labeled biotin conjugates. (
  • This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. (
  • He has been senior physician at Guy's Hospital since May 2018, a reader at King's College London since August 2022 and continues to study the immunobiology of Myeloid Malignancies and Neoplasms. (
  • IMSEAR at SEARO: Role of HSV antibodies in precancerous & cancerous lesions of the uterine cervix--a prospective study. (
  • Primary malignant neoplasms of the sweat glands are rare, constituting less than 1% of all primary malignant skin lesions 1 . (